Abstract
| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 629-640 |
| Number of pages | 12 |
| Journal | New England Journal of Medicine |
| Volume | 376 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Feb 1 2017 |
Keywords
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Carcinoma, Non-Small-Cell Lung/*drug therapy, Disease-Free Survival, Female, Humans, Lung Neoplasms/*drug therapy, Male, Middle Aged, Mutation, Pemetrexed/*administration dosage/adverse effects, Piperazines/*administration dosage/adverse effects, Platinum/administration dosage, Receptor, Epidermal Growth Factor/*antagonists inhibitors, Young Adult
Cite this
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. / Mok, Tony S.; Wu, Yi Long; Ahn, Myung Ju; Garassino, Marina C.; Kim, Hye Ryoun; Ramalingam, Suresh S.; Shepherd, Frances A.; He, Yong; Akamatsu, Hiroaki; Theelen, Willemijn S. M. E.; Lee, Chee K.; Sebastian, Martin; Templeton, Alison; Mann, Helen; Marotti, Marcelo; Ghiorghiu, Serban; Papadimitrakopoulou, Vassiliki A.
In: New England Journal of Medicine, Vol. 376, No. 7, 01.02.2017, p. 629-640.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
AU - Mok, Tony S.
AU - Wu, Yi Long
AU - Ahn, Myung Ju
AU - Garassino, Marina C.
AU - Kim, Hye Ryoun
AU - Ramalingam, Suresh S.
AU - Shepherd, Frances A.
AU - He, Yong
AU - Akamatsu, Hiroaki
AU - Theelen, Willemijn S. M. E.
AU - Lee, Chee K.
AU - Sebastian, Martin
AU - Templeton, Alison
AU - Mann, Helen
AU - Marotti, Marcelo
AU - Ghiorghiu, Serban
AU - Papadimitrakopoulou, Vassiliki A.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown. Methods In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. In all the patients, disease had progressed during receipt of first-line
AB - Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown. Methods In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. In all the patients, disease had progressed during receipt of first-line
KW - Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use, Carcinoma, Non-Small-Cell Lung/drug therapy, Disease-Free Survival, Female, Humans, Lung Neoplasms/drug therapy, Male, Middle Aged, Mutation, P
U2 - 10.1056/NEJMoa1612674
DO - 10.1056/NEJMoa1612674
M3 - Articolo
VL - 376
SP - 629
EP - 640
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 7
ER -